The goal of this clinical trial is to find out the efficacy of diosmin and hesperidin on postoperative early rehabilitation after primary total knee arthroplasty. The main questions it aims to answer are: Does diosmin and hesperidin combined drug decreases the lower extremity swelling, pain and increases the range of motion after primary total knee arthroplasty surgery compared to standard therapy group? Does diosmin and hesperidin combined drug decreases inflammation after total knee arthroplasty surgery. Participants will take diosmin and hesperidin in addition to standard therapy for 14 days after total knee arthroplasty surgery. Lower extremity swelling, pain and range of motion of the patients will be recorded in every visit.
Study Type
OBSERVATIONAL
Enrollment
190
Participants will take diosmin and hesperidin combination for 14 days after total knee replacement surgery.
Ankara Etlik City Hospital
Ankara, Yenimahalle, Turkey (Türkiye)
Lower extremity swelling
Lower extremity swelling is measured by measuring extremity diameters from 3 points (below patella, patella and above patella) and noted. Then percentage of increment or decrement of diameters is measured.
Time frame: From enrollment to the end of the treatment at 2 weeks
Pain
The Visual Analog Scale is used to describe patients' pain. It is a scale that describes pain by giving numbers from 0 to 10. 0 means no pain and 10 means extreme pain.
Time frame: From enrollment to the end of the treatment at 2 weeks
Range of motion
Knee range of motion is measured with goniometer.
Time frame: From enrollment to the end of the treatment at 2 weeks
Blood C-reactive protein value as an inflammotory marker
Time frame: From enrollment to the end of the treatment at 2 weeks
Blood erythrocyte sedimentation rate as an inflammotory marker
Time frame: From enrollment to the end of the treatment at 2 weeks
Blood neutrophil/lymphocyte rate as an inflammatory marker
Time frame: From enrollment to the end of the treatment at 2 weeks
Panimmune value (neutrophil x platelet x monocyte / lymphocyte) as an inflammatory marker
Time frame: From enrollment to the end of the treatment at 2 weeks
The systemic immune-inflammation index (neutrophils × platelets/lymphocytes) as an inflammatory marker
Time frame: From enrollment to the end of the treatment at 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.